Potent immunosuppressive agents, derivatives and uses
Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drugs mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof. Moreover, the analogs, like pateamine A, are valuable molecular probes for evaluation of eukaryotic translation initiation and as lead compounds for development of improved anticancer agents.
1. A method for modulating eIF4A comprising contacting a cell with a compound selected from the group consisting of:
(a)
(b)
wherein R 1 is selected from the group consisting of hydroxyalkene, methoxyalkene, dimethylamino alkene, and dimethylamino methyldiene,
(c)
(d)
(e)
(f)
(g)
(h)
(i)
wherein X is O, NH or NR, and Y is O, NH, or NR, wherein R is an alkyl or an aryl group, and
pharmaceutically acceptable salts thereof.
2. A method for inhibiting eIF4A-dependent translation initiation in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein
A-B is ethane, (E) and (Z)-ethene, (E) and (Z)-substituted ethene, ethyne;
K is hydrogen or a C1-C3 alkyl group;
Q is NH or O;
X is selected from the group consisting of hydrogen, hydroxy, alkoxy, alkyl, aminocarbonyl, amino, alkylamino, dialkylamino, and alkoxycarbonylamino;
Y is S, NH, or O;
Z is selected from the group consisting of hydrogen, hydroxy, aminocarbonyl, alkylamino, dialkylamino, and alkoxycarbonylamino, with the proviso that when R 4 is dimethylamino, Z is not t-butoxycarbonylamino;
R 1 is hydrogen or a C1-C3 alkyl group; and
R is selected from the group consisting of:
(a) alkenyl of formula:
wherein R 2 is selected from the group consisting of alkyl, alkylhydroxy, alkylalkoxy, alkylamino, alkylaminoalkyl, and alkylaminodialkyl;
(b) alkenylaryl of formula:
wherein R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, trifluoromethane, and fluoro;
(c) methyldienylpentyl of formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino, and dialkylamino; and
(d) methylalkenylpentyl of formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino, and dialkylamino.
3. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
8. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
10. The method of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt thereof, wherein
X is Q, and
Y is O, NH, or NR, wherein R is an alkyl or an aryl group.